Provided by Tiger Trade Technology Pte. Ltd.

Pacira Pharmaceuticals

25.05
-0.1600-0.63%
Post-market: 25.170.1200+0.48%19:32 EDT
Volume:560.25K
Turnover:14.08M
Market Cap:998.54M
PE:71.21
High:25.71
Open:25.37
Low:24.83
Close:25.21
52wk High:27.66
52wk Low:18.80
Shares:39.86M
Float Shares:36.37M
Volume Ratio:1.02
T/O Rate:1.54%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3518
EPS(LYR):0.1578
ROE:2.05%
ROA:1.48%
PB:1.49
PE(LYR):158.71

Loading ...

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Aug 06

RBC Adjusts Price Target on Pacira Biosciences to $25 From $24, Maintains Sector Perform Rating

MT Newswires Live
·
Aug 05

Pacira Biosciences Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

Pacira Q2 FY26 Returns to GAAP Profit of USD 4.7 Million; Revenue Rises 6% to USD 192.4 Million

Reuters
·
Aug 05

Pacira BioSciences Q2 Adj. EPS $0.73 Beats $0.65 Estimate, Sales $192.400M Beat $190.816M Estimate

Benzinga Earnings
·
Aug 05

Pacira Biosciences Q2 Revenue USD 192.4 Million Vs. IBES Estimate USD 190.8 Million

Reuters
·
Aug 05

Pacira Biosciences Q2 Cash & Investments USD 251 Million

THOMSON REUTERS
·
Aug 05

Pacira Biosciences Outlook FY Revenue USD 735-760 Million

THOMSON REUTERS
·
Aug 05

Pacira Biosciences Q2 Adjusted Ebitda USD 48.7 Million

THOMSON REUTERS
·
Aug 05

Pacira Biosciences, - Reiterates Fy2026 Exparel Net Product Sales Guidance $600 Mln-$620 Mln

THOMSON REUTERS
·
Aug 05

Will Pacira’s (PCRX) U.S. Manufacturing Shift for PCRX-201 Redefine Its Post-EXPAREL Narrative?

Simply Wall St.
·
Aug 02

Earning Preview: Pacira Pharmaceuticals this quarter’s revenue is expected to increase by 4.26%, and institutional views are bullish

Earnings Agent
·
Jul 29

Pacira BioSciences Announces New National Survey Revealing the Hidden Toll of Pain on America’s Workforce

GlobeNewswire
·
Jul 28

Pacira Therapeutics: PCRX-201 Progress and Key ASCEND Catalysts Support Buy Rating; $32 Price Target Reaffirmed

TIPRANKS
·
Jul 28

Pacira BioSciences Enrolls First Patient in Mid-stage Trial After Manufacturing Milestone

MT Newswires Live
·
Jul 27

Pacira transitions PCRX-201 to a U.S.-based manufacturing process

TIPRANKS
·
Jul 27

Pacira Transitions Pcrx-201 Gene Therapy to Scalable Commercial Manufacturing Process in Phase 2 Ascend Study

Reuters
·
Jul 27

Pacira Biosciences - Part a Ascend Enrollment Concluded; Topline Data Expected by End of 2026

THOMSON REUTERS
·
Jul 27

Pacira Biosciences Advances Pcrx-201 Development Program with Successful Transition to Scalable Commercial Manufacturing Process

THOMSON REUTERS
·
Jul 27

Pacira Biosciences to Report Q2 2026 Results, Host Conference Call

Reuters
·
Jul 22